Endocrinology Medical News about Osteoporosis Risedronate Ibandronate

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150mg and risedronate 150mg
Current Medical Research and Opinion, 10/22/09

Epstein S et al. – Risedronate 150mg once monthly has demonstrated less reduction of BTM and non–inferior BMD gains versus daily, whereas 150mg once monthly ibandronate has demonstrated BTM suppression within the premenopausal range and BMD gains superior to the daily regimen. Furthermore, ibandronate has demonstrated antifracture efficacy with intermittent dosing in two pooled analyses. Risedronate has yet to demonstrate anti–fracture efficacy with an extended (intermittent) dosing regimen.

<< Previous
Hospital volume influences the choice of operation for thyroid...

Next >>
Flexion contractures in secondary adrenal insufficiency

Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA
Osteoporosis International, 10/06/09 Relevance Score: 78%

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
Clinical Interventions in Aging, 11/12/09 Relevance Score: 69%

Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study
Journal of Bone and Mineral Metabolism, 11/09/09 Relevance Score: 66%

Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: Results from quantitative computed tomography-based finite element analysis of the vertebral body
Bone, 10/27/09 Relevance Score: 66%

Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism
Osteoporosis International, 10/30/09 Relevance Score: 65%